AI Portfolio Summary
In 2026 Q1, Merck & Co., Inc. maintained a portfolio of 15 distinct positions. The most significant new addition to the portfolio was EIKON THERAPEUTICS I, which now represents 5.05% of the total fund value. Conversely, Merck & Co., Inc. completely exited their position in XILIO THERAPEUTICS I.
Total Positions
15
Quarter
2026 Q1
Top Holding
MRNA (33.6%)
Top 10 Concentration
99.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-15 of 15
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MRNA
MODERNA INC
|
Healthcare | 33.56% | 24.64% |
#1
1
Prev: #2
|
7.0 | no change | no change |
P
S
|
2,308,190 | $117,256,052 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
PSNL
PERSONALIS INC
|
Healthcare | 25.60% | 40.47% |
#2
1
Prev: #1
|
6.5 | no change | no change |
P
S
|
14,044,943 | $89,466,287 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 18.40% | 21.75% |
#3
Prev: #3
|
6.0 | no change | no change |
P
S
|
772,165 | $64,313,623 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
N/A
ENTRADA THERAPE...
|
—
|
Unknown | 6.28% | 6.47% |
#4
Prev: #4
|
4.0 | no change | no change |
P
S
|
1,739,768 | $21,955,872 | — | 13F Filing | 2026-03-31 | 2026-05-13 | ||
|
N/A
EIKON THERAPEUT...
|
—
|
Unknown | 5.05% | — |
#5
Prev: #—
|
6.0 | 1,666,666 | no change |
NEW
|
1,666,666 | $17,633,326 | — | 13F Filing | 2026-03-31 | 2026-05-13 | ||
|
N/A
AKTIS ONCOLOGY ...
|
—
|
Unknown | 4.88% | — |
#6
Prev: #—
|
5.5 | 952,844 | no change |
NEW
|
952,844 | $17,046,379 | — | 13F Filing | 2026-03-31 | 2026-05-13 | ||
|
ALEC
ALECTOR INC
|
Healthcare | 2.18% | 2.00% |
#7
1
Prev: #6
|
1.9 | no change | no change |
P
S
|
3,545,719 | $7,623,297 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 1.94% | 1.14% |
#8
1
Prev: #7
|
1.8 | no change | no change |
P
S
|
272,351 | $6,784,263 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
EVAX
EVAXION BIOTECH...
|
Healthcare | 1.29% | 2.10% |
#9
4
Prev: #5
|
1.5 | no change | no change |
P
S
|
1,214,126 | $4,516,549 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.52% | 1.05% |
#10
2
Prev: #8
|
1.2 | no change | no change |
P
S
|
93,414 | $1,827,178 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
N/A
XILIO THERAPEUT...
|
—
|
Unknown | 0.26% | — |
#11
Prev: #—
|
3.6 | 105,982 | no change |
NEW
|
105,982 | $891,309 | — | 13F Filing | 2026-03-31 | 2026-05-13 | ||
|
CARM
CARISMA THERAPE...
|
Healthcare | 0.01% | 0.02% |
#12
2
Prev: #10
|
1.0 | no change | no change |
P
S
|
1,473,240 | $47,880 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
NEUP
NEUPHORIA THERA...
|
Healthcare | 0.01% | 0.01% |
#13
2
Prev: #11
|
1.0 | no change | no change |
P
S
|
10,027 | $40,810 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
HURA
TUHURA BIOSCIEN...
|
Healthcare | 0.01% | 0.00% |
#14
2
Prev: #12
|
2.5 | 5,495 | 39.4% |
P
S
|
19,445 | $34,807 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
XLO
XILIO THERAPEUT...
|
Healthcare | 0.00% | 0.34% |
Sold All 😨
(Was: #9) |
0.0 | -1,483,758 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 |
Showing 1-15 of 15 holdings